Navigation Links
ImQuest Receives $6.4 M Five Year Award from NIH to Develop Long-Lasting Combination Topical Microbicides To Prevent HIV Transmission
Date:8/6/2008

products and the proposed combination microbicide will provide a three layer barrier to HIV infection. Initially, the product will inactivate HIV and HIV-infected cells in the semen upon introduction to the vagina. Secondly, two separate products in the combination will prevent the initial attachment and subsequent entry of virus into the vaginal target cells, preventing infection. Finally, the third and most potent activity of the product will prevent the critical action of the virus-encoded reverse transcriptase inside the cell. Key features of the development program include the formulation of the product for delivery as gels or intravaginal rings, pharmacokinetic and pharmacodynamic evaluations to demonstrate the feasibility of the formulated product for use, acceptability studies to assure that the final product will be used by the women it is intended to protect, and the IND-directed preclinical and clinical activities required to initiate FDA-approved human clinical trials for the unique final product.

ImQuest CEO, Joseph McGuirl states, "We are highly honored that the NIH has seen fit to fund this important microbicide development program and we look forward to working closely with our team of academic collaborators and the NIH to successfully achieve our goals."

ImQuest Life Sciences, a privately held U.S. company located in Frederick, Maryland specializes in early stage drug development of novel compounds for the treatment of infectious disease and cancer. ImQuest BioSciences, also located in Frederick, Maryland, is a leading provider of anti-infective therapeutic and microbicide development services to the biotechnology and pharmaceutical industry.

For further information regarding this press release please contact:

Robert W. Buckheit, Jr., Ph.D.

Executive Vice President and Chief Scientific Officer

ImQuest Life Sciences, Inc.

301-696-0274

rbuckheit@imquest.c
'/>"/>

SOURCE ImQuest BioSciences
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. ImQuest Awarded SBIR Grant to Define the Mechanism of Action of Their Lead Anti-HIV Therapeutic Compound IQP-0410
2. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
3. Ciphergen Biosystems Receives Noncompliance Letter From The Nasdaq Stock Market
4. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
5. Anesiva Receives FDA Approval for Zingo(TM), a New, Innovative Product to Reduce Pain Associated with Needle Insertion Procedures in Children
6. IsoTis Receives FDA Clearance for Accell Family of Products
7. Actavis Receives Approval of Fentanyl Transdermal System in the U.S.
8. AGA Medical Corporation Receives FDA and CE Mark Approvals for the AMPLATZER Vascular Plug II
9. IDM Pharma Receives Not Approvable Letter for Mifamurtide (L-MTP-PE) for the Treatment of Osteosarcoma
10. XTL Receives Staff Letter From NASDAQ
11. XTL Receives Staff Letter From NASDAQ; XTL may Transfer its ADR Listing to the NASDAQ Capital Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... January 15, 2014 This webinar will ... and clinical safety assessment in biosimilars. , Regulatory frameworks ... biosimilar drug development, however the complex nature of biopharmaceuticals ... safety and efficacy extremely challenging. Based on the specific ...
(Date:1/15/2014)... TX (PRWEB) January 15, 2014 More ... disease, and about 1 in 3 seniors will die ... source ). These jaw-dropping figures have shocked many Americans ... and, hopefully, help prevent these tragic age-related cognitive disorders. ...
(Date:1/15/2014)... The Microcompetition with Foreign DNA theory explains how latent viruses ... is the Epstein Barr Virus (EBV), and one of these ... chronic inflammatory disease that destroys the body’s joints. As predicted ... high concentrations of EBV DNA in their bodies (1). ...
(Date:1/15/2014)... 2013 was a banner year of continued innovation ... continued independent research led by the team at Wake ... million grant from the Susanne Marcus Collins Foundation, had ... reviewed journal, Amy Grant highlighted Brainwave Optimization® in First ...
Breaking Biology Technology:Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2Biohack Pure Offers 5 Tips for Increasing Memory in 2014 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 2Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 3
... BNVI ) will present findings on the mechanism ... BN108 at the American Association of,Cancer Research (AACR) being ... CA, April 12 - 16, 2008., Bionovo,s poster ... death) induced by BN107 and BN108. As explained by ...
... Announces Change to Unaudited Financial Results Released March 18, ... ... Bulletin Board: NGNM) announced today that it had filed with the,Securities and Exchange ... A copy of this annual report can be found at, http://www.SEC.gov ., ...
... researchers at ... with internal solutions, REDWOOD CITY, Calif., April 15 ... life science researchers, and,Pfizer Pharmaceuticals, Inc. (NYSE: PFE ... a strategic,partnership today. This new multi-year partnership promotes enterprise-wide,deployment ...
Cached Biology Technology:Bionovo to Present Recent Findings of BN107 and BN108, Its Anticancer Agents, at the American Association of Cancer Research 2NeoGenomics Files Annual Report on Form 10-KSB with the SEC 2Ingenuity Systems and Pfizer Announce Strategic Partnership for Pathway Analysis 2Ingenuity Systems and Pfizer Announce Strategic Partnership for Pathway Analysis 3
(Date:7/9/2014)... be able to cope with the rising salinity of Arctic ... today is best known for its tundra and polar bear ... 38 million years ago during what is known as the ... temperate forest with brackish water, home to a variety of ... giant tortoises. Much of what is known about the region ...
(Date:7/9/2014)... pain and fever but often can be defeated with antibiotics ... hard to beat. Now, scientists have built a new weapon ... Published in the journal ACS Applied Materials & Interfaces ... kill more of them than medicine alone. , David Leong, ... lie in wait, undetectable in the human body or in ...
(Date:7/9/2014)... sparrow-sized fossil from China challenges the commonly held belief ... the ability to fly. The birdlike fossil is actually ... the remains of a tiny tree-climbing animal that could ... Museum in Blanding, Utah, and Alan Feduccia of the ... Journal of Ornithology . , The fossil of ...
Breaking Biology News(10 mins):Shark teeth analysis provides detailed new look at Arctic climate change 2Shark teeth analysis provides detailed new look at Arctic climate change 3Researchers declassify dinosaurs as being the great-great-grandparents of birds 2
... , WALL, N.J., Dec. 3 ... in wireless public safety and finger-based biometric identification solutions, ... Special Shareholder Meeting held today approved the sale of ... Inc. Of the shares voted, 98.6% were cast in ...
... Preliminary Press Conference Topics Last Call! Press ... Attention PIOs: Sending Press Releases to Fall meeting ... News Media registration information News Media Registration ... coming For important information regarding visas ...
... Have you ever felt overly upset by a social ... Scientists have long known that opium-like painkillers, called opioids, ... emotional stress. Now, a new study reviewed by Faculty of ... in the gene for the opioid receptor can determine the ...
Cached Biology News:BIO-key(R) Shareholders Overwhelmingly Approve Sale of Law Enforcement Division 2BIO-key(R) Shareholders Overwhelmingly Approve Sale of Law Enforcement Division 3AGU fall meeting: Preliminary press conference topics, press pre-registration deadline 2AGU fall meeting: Preliminary press conference topics, press pre-registration deadline 3AGU fall meeting: Preliminary press conference topics, press pre-registration deadline 4AGU fall meeting: Preliminary press conference topics, press pre-registration deadline 5AGU fall meeting: Preliminary press conference topics, press pre-registration deadline 6
Request Info...
... from E. coli is a ... also contains both 5'--3'and 3'--5' ... activity enables the enzyme to ... the DNA as starting points ...
Request Info...
... E. coli containing a clone of the human ... Topoisomerase II alters the topological state of nucleic ... a transient break which generates a separate DNA ... double-stranded DNA passage mechanism, the enzyme can relax ...
Biology Products: